What one share of Lyell Immunopharma holds
We are a late-stage clinical cell therapy company advancing a pipeline of proprietary next-generation autologous chimeric antigen receptor (CAR) T-cell product candidates for patients with cancer. Our goal is to fully realize the curative potential of cell therapy for patients with hematologic malignancies and solid tumors.
Lyell Immunopharma’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $0.00 |
|---|---|
| Profit | −$11.84 |
| Capex (buildings and equipment) | $0.03 |
| Free cash flow | −$6.38 |
| Cash and investments | $9.74 |
| Book value | $9.99 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2019 | — | −$476.61 | $59.12 | $86.30 | — | −$409.31 |
| 2020 | — | −$313.85 | $77.66 | −$320.34 | — | −$375.76 |
| 2021 | — | −$36.82 | $9.64 | −$28.22 | — | $76.61 |
| 2022 | — | −$14.82 | $1.97 | −$15.69 | — | $66.78 |
| 2023 | $0.01 | −$18.70 | $0.21 | −$13.26 | — | $51.58 |
| 2024 | $0.00 | −$26.23 | $0.04 | −$12.46 | — | $25.97 |
| 2025 | $0.00 | −$16.06 | $0.05 | −$8.82 | — | $11.68 |
Common questions about Lyell Immunopharma
How much does one share of Lyell Immunopharma earn?
Over the last 12 months, Lyell Immunopharma lost $11.84 for each share on $0.00 of sales.
Does Lyell Immunopharma pay a dividend?
Lyell Immunopharma didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is Lyell Immunopharma’s book value per share?
Lyell Immunopharma’s book value is $9.99 per share: what would be left for each share if it sold everything at the values on its books and paid every debt, as of June 30, 2026.
How much cash and debt does each share of Lyell Immunopharma have?
Each share of Lyell Immunopharma has $9.74 of cash and investments, as of June 30, 2026.
What is Lyell Immunopharma’s free cash flow per share?
−$6.38 per share over the last 12 months. Free cash flow is the cash left over after spending on buildings and equipment.
Has Lyell Immunopharma bought back shares?
Lyell Immunopharma’s share count rose about 6197% from 2019 to 2025. That dilution means each share owns a smaller slice of the company.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.